“Our third quarter total revenue of $9.4 million, which represented a 20% increase over last quarter, and a 31% increase over the third quarter of 2020, was our third highest quarterly revenue total since 2018. Increased portfolio of clinical evidence around iCAD’s Xoft® brain intraoperative radiation therapy (IORT) with new data presented at American Association of Neurological Surgeons demonstrating significant improvement in overall survival in recurrent glioblastoma patients after treatment These technologies provide critical, risk-adaptive solutions for clinicians facing complex screening challenges when personalizing wellness assessments regardless of a patient’s ethnicityĬontinued commercial focus in the Therapy business drove $3.4 million in revenues, which represents a 10% increase in sequential quarter revenues, supported by the ongoing demand for dermatology controller installations, which continues to benefit from favorable market conditions from both a regulatory and reimbursement standpoint Launched ProFound AI ® Risk (3D mammography), alongside an enhanced version of PowerLook ® Density Assessment. product sales increasing 56% compared to last quarter and Europe, with improving enterprise sales in the third quarter resulting in a 41% increase in sequential quarter Detection product revenues, with U.S. Net loss for the three-month and nine-month periods ended September 30, 2021, were $2.2 million and $7.1 million, respectively, compared to $1.8 million and $16.0 million in the three and nine-month periods ended September 30, 2020, respectively.Įxperienced continued market demand for ProFound AI® Risk, the first and only commercially available clinical decision support tool providing two-year breast cancer risk estimation personalized for each woman, in the U.S. This represents 31% growth over the third quarter 2020 and 20% growth over the second quarter 2021.
Revenues for the three-month and nine-month periods ended Septemwere $9.4 million and $25.8 million, respectively, compared to $7.1 million and $19.2 million in the three and nine month periods ended September 30, 2020, respectively.
(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and nine months ended September 30, 2021. Company to Host Conference Call & Webcast today at 4:30 PM ET.
ICCAD’22 is financially sponsored by Tunisian Association of Technology and Sustainable Development (ATTeDD).- Xoft ® Product Revenue Reflected a 34% Sequential Quarter Increase in the Third Quarter of 2021 with Continued Surge in Dermatology Controller Installations. ICCAD’22 will be technically sponsored by IEEE Systems, Man and Cybernetics Society, Polytech Grenoble and IEEE Society.
#ICAD PARIS FULL#
Please note that at least one full paying author of each accepted paper must register for the conference before the indicated deadline.
The technical program will include plenary lectures, regular technical sessions, and special sessions. This conference will provide a remarkable opportunity for the academic and industrial communities to address new challenges, share solutions and discuss future research directions. It brings together experts from industry, governments and academia, experienced in engineering, design and research. Our conference is a forum for presenting excellent results and new challenges facing the field of the reliability and availability of Control, Automation and Diagnosis. ICCAD’22 will be held in hybrid mode (both in presence and online) in July 13-15, 2022 at Lisbon, Portugal.
0 kommentar(er)
